This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2004;364(9445):1577-8; author reply 1578-9.

doi: 10.1016/S0140-6736(04)17302-9.

Should rosuvastatin be withdrawn from the market?

John J P Kastelein

PMID: 15519620
DOI: 10.1016/S0140-6736(04)17302-9

Comment

Should rosuvastatin be withdrawn from the market?

John J P Kastelein. Lancet. 2004.

. 2004;364(9445):1577-8; author reply 1578-9.

doi: 10.1016/S0140-6736(04)17302-9.

Author

John J P Kastelein

PMID: 15519620
DOI: 10.1016/S0140-6736(04)17302-9

No abstract available

PubMed Disclaimer

Comment on

Dangers of rosuvastatin identified before and after FDA approval.
Wolfe SM. Wolfe SM. Lancet. 2004 Jun 26;363(9427):2189-90. doi: 10.1016/S0140-6736(04)16513-6. Lancet. 2004. PMID: 15220045 No abstract available.

Similar articles

Should rosuvastatin be withdrawn from the market?
Cohen JS. Cohen JS. Lancet. 2004 Oct 30-Nov 5;364(9445):1579; discussion 1579-80. doi: 10.1016/S0140-6736(04)17304-2. Lancet. 2004. PMID: 15519624 No abstract available.
Dangers of rosuvastatin identified before and after FDA approval.
Wolfe SM. Wolfe SM. Lancet. 2004 Jun 26;363(9427):2189-90. doi: 10.1016/S0140-6736(04)16513-6. Lancet. 2004. PMID: 15220045 No abstract available.
Safety and efficacy of rosuvastatin.
Olsson GO. Olsson GO. Lancet. 2004 Jul 10-16;364(9429):135. doi: 10.1016/S0140-6736(04)16616-6. Lancet. 2004. PMID: 15246717 No abstract available.
[Lipid lowering by rosuvastatin: how do statins differ?].
Laufs U. Laufs U. Dtsch Med Wochenschr. 2015 Mar;140(5):313. doi: 10.1055/s-0041-100713. Epub 2015 Mar 3. Dtsch Med Wochenschr. 2015. PMID: 25734669 Review. German. No abstract available.
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS, Milionis HJ, Elisaf MS. Kostapanos MS, et al. Am J Cardiovasc Drugs. 2010;10(1):11-28. doi: 10.2165/13168600-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20104931 Review.

See all similar articles

Cited by

Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
Sakaeda T, Kadoyama K, Okuno Y. Sakaeda T, et al. PLoS One. 2011;6(12):e28124. doi: 10.1371/journal.pone.0028124. Epub 2011 Dec 20. PLoS One. 2011. PMID: 22205938 Free PMC article.
Evidence-based prescribing of statins: a developing world perspective.
Ong HT. Ong HT. PLoS Med. 2006 Mar;3(3):e50. doi: 10.1371/journal.pmed.0030050. Epub 2006 Feb 21. PLoS Med. 2006. PMID: 16478294 Free PMC article.
Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.
Kasliwal R, Wilton LV, Cornelius V, Aurich-Barrera B, Shakir SA. Kasliwal R, et al. Drug Saf. 2007;30(2):157-70. doi: 10.2165/00002018-200730020-00005. Drug Saf. 2007. PMID: 17253880

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information